NIPH Clinical Trials Search

The study for efficacy of teneligliptin in non-alcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus

Basic Information

Recruitment status	Complete: follow-up complete
Health condition(s) or Problem(s) studied	non-alcoholic fatty liver disease/type 2 diabetes mellitus
Date of first enrollment	2014/02/03
Target sample size	100
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	administration of teneligliptin with diet and exercise therapy diet and exercise therapy only (and administration of glimepiride as needed)

Outcome(s)

Primary Outcome	improvement in liver stiffness
Secondary Outcome	improvement in physical findings and laboratory data

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	70years-old
Gender	Male and Female
Include criteria
Exclude criteria	1) intake more than 20g/day of ethanol 2) HBsAg and/or HCV Ab positive 3) history of hepatic disease, such as autoimmune liver disease, hemochromatosis and Wilson's disease 4) history of diabetes ketosis and/or diabetic coma 5) during pregnancy